Nervgen Pharma CORP F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
NASDAQ
NervGen Pharma Corp. has amended its registration statement to increase its potential at-the-market offering of common shares, debt securities, subscription receipts, warrants, and units to $250 million.